BR0315431A - Taxanos covalentemente ligados a ácido hialurÈnico ou derivados de ácido hialurÈnico - Google Patents

Taxanos covalentemente ligados a ácido hialurÈnico ou derivados de ácido hialurÈnico

Info

Publication number
BR0315431A
BR0315431A BR0315431-9A BR0315431A BR0315431A BR 0315431 A BR0315431 A BR 0315431A BR 0315431 A BR0315431 A BR 0315431A BR 0315431 A BR0315431 A BR 0315431A
Authority
BR
Brazil
Prior art keywords
hyaluronic acid
taxanes
covalently linked
acid derivatives
derivatives
Prior art date
Application number
BR0315431-9A
Other languages
English (en)
Inventor
Luca Gilda De
Bettolo Rinaldo Marini
Luisa Maria Migneco
Original Assignee
Fidia Farmaceutici
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Farmaceutici filed Critical Fidia Farmaceutici
Publication of BR0315431A publication Critical patent/BR0315431A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof

Abstract

"TAXANOS COVALENTEMENTE LIGADOS A áCIDO HIALURÈNICO OU DERIVADOS DE áCIDO HIALURÈNICO". A presente invenção refere-se a taxanos solúveis em água covalentemente ligados a ácido hialurónico ou derivados de ácido hialurónico, e em particular a paclitaxel e docetaxel, úteis para a preparação de composições farmacêuticas a serem utilizadas no campo da oncologia, no tratamento de distúrbios auto-imunes e de restenose. A invenção refere-se também ao processo para preparar taxanos covalentemente ligados a ácido hialurónico ou derivados de ácido hialurónico por síntese direta entre moléculas de ácido hialurónico e do taxano ou por síntese indireta pela introdução de um espaçador entre o ácido hialurónico ou derivado de ácido hialurónico e o taxano.
BR0315431-9A 2002-10-18 2003-10-10 Taxanos covalentemente ligados a ácido hialurÈnico ou derivados de ácido hialurÈnico BR0315431A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000271A ITPD20020271A1 (it) 2002-10-18 2002-10-18 Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
PCT/EP2003/011239 WO2004035629A2 (en) 2002-10-18 2003-10-10 Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives

Publications (1)

Publication Number Publication Date
BR0315431A true BR0315431A (pt) 2005-08-16

Family

ID=32104794

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315431-9A BR0315431A (pt) 2002-10-18 2003-10-10 Taxanos covalentemente ligados a ácido hialurÈnico ou derivados de ácido hialurÈnico

Country Status (23)

Country Link
US (2) US7897584B2 (pt)
EP (2) EP2045270B1 (pt)
JP (1) JP4704753B2 (pt)
KR (1) KR101076414B1 (pt)
CN (1) CN1705683B (pt)
AT (1) ATE420117T1 (pt)
AU (1) AU2003267441B2 (pt)
BR (1) BR0315431A (pt)
CA (2) CA2502531C (pt)
DE (1) DE60325760D1 (pt)
DK (1) DK1560854T3 (pt)
ES (2) ES2320439T3 (pt)
HK (1) HK1082753A1 (pt)
HR (1) HRP20050416B1 (pt)
IL (1) IL168086A (pt)
IT (1) ITPD20020271A1 (pt)
NO (1) NO333042B1 (pt)
NZ (2) NZ547668A (pt)
PL (2) PL216861B1 (pt)
PT (1) PT1560854E (pt)
RU (1) RU2384593C2 (pt)
SI (1) SI1560854T1 (pt)
WO (1) WO2004035629A2 (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923431B2 (en) 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
EP1530465B2 (en) * 2002-06-26 2015-12-16 MediGene AG Method of producing a cationic liposomal preparation comprising a lipophilic compound
CN101001649B (zh) 2004-07-09 2011-08-31 弗罗桑医疗设备公司 包括透明质酸的止血组合物及其制备方法
US8354392B2 (en) 2005-07-06 2013-01-15 Seikagaku Corporation Drug-introduced photo-crosslinked hyaluronic acid derived gel
ITPD20050242A1 (it) 2005-08-03 2007-02-04 Fidia Farmaceutici Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
WO2007083984A1 (en) * 2006-01-23 2007-07-26 Gwangju Institute Of Science And Technology Conjugate comprising pharmaceutical active compound covalently bound to mucoadhesive polymer and transmucosal delivery method of pharmaceutical active compound using the same
IE20060049A1 (en) * 2006-01-25 2007-08-08 Eurand Pharmaceuticals Ltd A novel drug delivery system: use of hyaluronic acid as a carrier moleclue for different classes of therapeutic active agents
CA2657823A1 (en) * 2006-08-04 2008-02-07 Novozymes Biopolymer A/S Branched hyaluronic acid and method of manufacture
WO2008089258A2 (en) * 2007-01-16 2008-07-24 Cappella, Inc. Drug eluting medical device using polymeric therapeutics
ITMI20071267A1 (it) * 2007-06-22 2008-12-23 Fidia Farmaceutici Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative
ITMI20071341A1 (it) 2007-07-05 2009-01-06 Fidia Farmaceutici Derivati di acido ialuronico contenenti gruppi in grado di rilasciare no
IE20070900A1 (en) * 2007-12-12 2009-06-24 Eurand Pharmaceuticals Ltd New anticancer conjugates
KR101224711B1 (ko) 2008-01-30 2013-01-21 유니버시티 오브 캔사스 림프관내 화학요법 약물 담체
EP2259803B2 (en) 2008-02-29 2019-03-13 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
US9925209B2 (en) 2008-03-19 2018-03-27 The Board Of Regents Of The University Of Oklahoma Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same
US9687559B2 (en) 2008-03-19 2017-06-27 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
IT1391006B1 (it) * 2008-10-08 2011-10-27 Fidia Farmaceutici Uso terapeutico di nuove preparazioni farmaceutiche contenenti farmaci antitumorali legati all'acido ialuronico nel trattamento delle neoplasie
JP5572152B2 (ja) * 2008-04-22 2014-08-13 フィディア ファルマチェウティチ ソシエタ ペル アチオニ 腫瘍の治療におけるヒアルロン酸に結合した抗腫瘍薬を含む新規医薬製剤の治療的使用
CA2773755C (en) * 2008-09-09 2017-04-25 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
WO2010053140A1 (ja) 2008-11-05 2010-05-14 国立大学法人 東京医科歯科大学 ヒアルロン酸誘導体、およびその医薬組成物
IT1397247B1 (it) * 2009-05-14 2013-01-04 Fidia Farmaceutici Nuovi agenti regolatori dell'attivita' citochinica
IT1399351B1 (it) * 2009-06-16 2013-04-16 Fidia Farmaceutici Procedimento per la sintesi di coniugati di glicosamminoglicani (gag) con molecole biologicamente attive, coniugati polimerici e usi relativi
KR20110032561A (ko) * 2009-09-23 2011-03-30 포항공과대학교 산학협력단 약물 전달체의 표적 특이성 조절 방법, 표적 특이적 약물 전달체, 및 표적-비특이적 약효 장기 지속성 약물 전달체
US8722644B2 (en) 2010-01-04 2014-05-13 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer
WO2012086857A1 (ko) * 2010-12-21 2012-06-28 (주)파낙스이엠 광역학 진단 또는 치료를 위한 결합체 및 이의 제조방법
JP6241624B2 (ja) 2012-03-06 2017-12-06 フェロサン メディカル デバイシーズ エイ／エス 止血ペーストを収容する加圧容器
CN104168927B (zh) * 2012-03-27 2016-10-05 泰尔茂株式会社 涂布组合物及医疗器械
EP2825216B1 (en) 2012-06-12 2015-08-19 Ferrosan Medical Devices A/S Dry haemostatic composition
KR102130864B1 (ko) 2012-09-05 2020-07-08 추가이 세이야쿠 가부시키가이샤 아미노산 및 스테릴기가 도입된 히알루론산 유도체
US9635795B2 (en) 2012-10-23 2017-04-25 International Business Machines Corporation Multiple expansion card insertion and extraction tool
CN103641925B (zh) * 2012-11-27 2016-08-17 王晖 水溶性多聚糖与紫杉烷类化合物的共价聚化合物，其制备方法及医药用途
WO2014202760A2 (en) 2013-06-21 2014-12-24 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
US10098962B2 (en) 2013-07-10 2018-10-16 Seikagaku Corporation Glycosaminoglycan derivative and method for producing same
US10675354B2 (en) 2013-07-10 2020-06-09 Seikagaku Corporation Glycosaminoglycan derivative and method for producing same
EP3470094B1 (en) 2013-12-11 2020-07-22 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
CN103861116A (zh) * 2014-03-06 2014-06-18 沈阳药大制剂新技术有限公司 一种抗肿瘤药物的前体药物及其制备和应用
CA2951808C (en) * 2014-07-31 2022-06-21 Sebastiano SCIUTO Derivatives obtained from hyaluronic acid and carnosine
CN104198707B (zh) * 2014-09-12 2016-09-14 范飞舟 N-乙酰氨基葡萄糖在制备检测肿瘤的试剂盒中的应用
JP6726852B2 (ja) 2014-10-13 2020-07-22 フェッローサン メディカル ディバイス エー／エス 止血および創傷治癒に使用するための乾燥組成物
CN104491875A (zh) * 2014-12-22 2015-04-08 中国药科大学 一种基于透明质酸-难溶性药物前药的自聚纳米系统的制备方法
AU2015371184B2 (en) 2014-12-24 2020-06-25 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
CA2972866C (en) * 2015-01-09 2023-08-22 Seikagaku Corporation Chondroitin sulfate derivative and agent for treating bladder diseases
CA2985502A1 (en) * 2015-05-29 2016-12-08 Albatross Technologies Limited Cross-linked hyaluronic acid for drug delivery and pharmaceutical preparation using same
CA2986981A1 (en) 2015-07-03 2017-01-12 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
CN108178803B (zh) * 2017-09-25 2020-03-10 温州医科大学 一种载药的肉桂醛-葡聚糖聚合物自组装纳米粒的制备及其抗肿瘤应用
WO2019098393A1 (ja) 2017-11-15 2019-05-23 中外製薬株式会社 ポリエチレングリコールにより修飾されたヒアルロン酸誘導体
CN108219029A (zh) * 2018-03-22 2018-06-29 盐城师范学院 一种水溶性卡巴他赛抗癌药物的制备方法
CN108467439A (zh) * 2018-03-22 2018-08-31 盐城师范学院 一种水溶性紫杉醇抗癌药物的制备方法
EP4321182A2 (en) 2018-05-09 2024-02-14 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition
EP3812376A4 (en) * 2018-06-20 2022-08-17 Santolecan Pharmaceuticals LLC PACLITAXEL-LIPID-POLYSACCHARIDE DOUBLE-TYPE CONJUGATE, METHOD FOR PREPARING IT AND ITS USE
IT201800009731A1 (it) * 2018-10-25 2020-04-25 Fidia Farm Spa Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante
CN111588914A (zh) * 2019-12-31 2020-08-28 辽宁垠艺生物科技股份有限公司 介入或植入医疗器械的药物涂层及其制备方法
IT202000007747A1 (it) * 2020-04-10 2021-10-10 Fidia Farm Spa Coniugato acido ialuronico-paclitaxel nel trattamento del mesotelioma
IT202000008209A1 (it) * 2020-04-17 2021-10-17 Fidia Farm Spa Procedimento di sintesi di un coniugato acido ialuronico-paclitaxel
CN111892668B (zh) * 2020-07-03 2022-07-12 广东工业大学 一种化合物及其制备方法、荧光探针和抗肿瘤药物
KR20230040957A (ko) * 2020-07-15 2023-03-23 코발 바이오파마 (상하이) 컴퍼니 리미티드 치료제를 국소 전달하기 위한 약물 전달 시스템 및 이의 용도
CN114870031B (zh) * 2022-05-20 2023-07-07 四川大学 一种cd44靶向的紫杉烷类纳米晶体及其制备方法与应用
WO2024038087A1 (en) * 2022-08-16 2024-02-22 Synartro Ab Method for preparing sterile compositions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
GB8713662D0 (en) * 1987-06-11 1987-07-15 Skandigen Ab Hyaluronic acid derivatives
IT1219587B (it) 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US5356883A (en) * 1989-08-01 1994-10-18 Research Foundation Of State University Of N.Y. Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use
DE69125595T2 (de) * 1990-10-18 1997-11-13 Shiseido Co Ltd Kombination von hyaluronsäure mit einem medizinischen bestandteil, und seine herstellung
JP2604930B2 (ja) * 1990-12-14 1997-04-30 株式会社ディ・ディ・エス研究所 ヒアルロン酸およびコンドロイチン誘導体
WO1993024476A1 (en) * 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
WO1994019376A1 (en) * 1993-02-26 1994-09-01 Drug Delivery System Institute, Ltd. Polysaccharide derivative and drug carrier
US5616568A (en) 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
ITPD940054A1 (it) 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
CZ297979B6 (cs) 1996-03-12 2007-05-16 Pg-Txl Company, L. P. Kompozice obsahující protinádorové lécivo konjugované s ve vode rozpustným polymerem, její pouzití pro výrobu léciva a implantovatelná lékarská pomucka
CA2175282A1 (en) 1996-04-29 1997-10-30 Rudolf Edgar Falk Use of forms of hyaluronic acid (ha) for the treatment of cancer
CA2208924A1 (en) 1997-07-09 1999-01-09 Hyal Pharmaceutical Corporation Sparing paclitaxel by the use of hyaluronan
EP1082963A4 (en) * 1998-05-20 2004-03-17 Chugai Pharmaceutical Co Ltd MEDICINE FOR HYALURONIC ACID-ASSOCIATED JOINT DISEASES
ITPD980169A1 (it) 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
AU8889998A (en) 1998-08-21 2000-03-14 Pharmachemie B.V. Water soluble analogs and prodrugs of paclitaxel
NZ512676A (en) 1999-01-13 2003-01-31 Meditech Res Ltd A composition and method for the enhancement of the efficacy of drugs
JP2001081103A (ja) * 1999-09-13 2001-03-27 Denki Kagaku Kogyo Kk ヒアルロン酸結合薬剤
US6593308B2 (en) 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
CA2395493C (en) 1999-12-28 2010-06-22 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
IT1317358B1 (it) 2000-08-31 2003-06-16 Fidia Advanced Biopolymers Srl Derivati cross-linkati dell'acido ialuronico.
IT1317359B1 (it) 2000-08-31 2003-06-16 Fidia Advanced Biopolymers Srl Polisaccaridi percarbossilati, quali l'acido ialuronico, processo perla loro preparazione e loro impiego in campo farmaceutico e

Also Published As

Publication number Publication date
CA2783175C (en) 2013-12-24
PT1560854E (pt) 2009-04-15
SI1560854T1 (sl) 2009-06-30
NZ540034A (en) 2007-11-30
US20060116346A1 (en) 2006-06-01
DE60325760D1 (de) 2009-02-26
HRP20050416B1 (hr) 2013-09-30
EP2045270A3 (en) 2009-06-03
EP1560854A2 (en) 2005-08-10
JP4704753B2 (ja) 2011-06-22
PL216861B1 (pl) 2014-05-30
WO2004035629A9 (en) 2005-07-07
US8034795B2 (en) 2011-10-11
NZ547668A (en) 2008-04-30
DK1560854T3 (da) 2009-04-20
US20110159052A1 (en) 2011-06-30
CN1705683A (zh) 2005-12-07
JP2006504747A (ja) 2006-02-09
RU2384593C2 (ru) 2010-03-20
ITPD20020271A1 (it) 2004-04-19
ES2320439T3 (es) 2009-05-22
CN1705683B (zh) 2010-04-28
NO20052399D0 (no) 2005-05-18
NO20052399L (no) 2005-05-18
AU2003267441A1 (en) 2004-05-04
WO2004035629A8 (en) 2005-06-09
EP1560854B1 (en) 2009-01-07
WO2004035629A2 (en) 2004-04-29
RU2005115116A (ru) 2006-01-20
EP2045270B1 (en) 2015-05-06
ES2544481T3 (es) 2015-08-31
WO2004035629A3 (en) 2004-06-24
KR20050065595A (ko) 2005-06-29
IL168086A (en) 2010-11-30
EP2045270A2 (en) 2009-04-08
KR101076414B1 (ko) 2011-10-25
PL376349A1 (en) 2005-12-27
ATE420117T1 (de) 2009-01-15
HRP20050416A2 (en) 2006-02-28
HK1082753A1 (en) 2006-06-16
NO333042B1 (no) 2013-02-18
AU2003267441B2 (en) 2010-01-14
US7897584B2 (en) 2011-03-01
CA2502531C (en) 2012-10-02
CA2502531A1 (en) 2004-04-29
PL392566A1 (pl) 2010-11-22
CA2783175A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
BR0315431A (pt) Taxanos covalentemente ligados a ácido hialurÈnico ou derivados de ácido hialurÈnico
RS20080167A (en) Novel improved compositions for cancer therapy
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
CY1116156T1 (el) Παραγωγα πυριμιδινης συνδεδεμενα με οξυγονο
DE60031268D1 (de) Verfahren und zusammansetzung zur behandlung von krebs
DE60003863D1 (de) Dioxocyclopentylhydroxamsäure
GB0313612D0 (en) Organic compounds
TNSN07322A1 (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
CY1112727T1 (el) Παραγωγα κυκλοβουτυλ αμινης βενζοθειαζολης και η χρηση αυτων ως προσδετες των υποδοχεων ισταμινης-3
CY1110896T1 (el) Μια νεα αντιμυκητιακη συνθεση
CR9182A (es) Derivado de quinolina, su uso, preparacion y medicamento que lo contiene
CY1110401T1 (el) Παραγωγα των 1-φαινυλαλκανοκαρβοξυλικων οξεων για την αντιμετωπιση των νευροεκφυλιστικων νοσων
BR0307518A (pt) Composição farmacêutica
EA201070193A1 (ru) Лечение детских опухолей
DE602004025557D1 (de) Metallorganische komplexe auf manganbasis, pharmazeutische zusammensetzungen und diätetische produkte
GB2430365B (en) High-purity texaphyrin metal complexes
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
ATE537162T1 (de) Vitamin-d-derivate, die auf den nuklearen vitamin-d-rezeptor wirken, deren herstellung und deren anwendungen
CY1107483T1 (el) Παραγωγα πυριδαζινης, η χρηση τους ως φαρμακευτικα σκευασματα και η διαδικασια παρασκευης τους
ATE272400T1 (de) Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren
ATE531766T1 (de) Hochreine texaphyrinmetallkomplexe
LV15575A (lv) Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana
DE60305520D1 (de) 2" oxo-voruscharin und derivaten
UA93197C2 (ru) Производные пиразолиламинопиридина, способ их получения, их применения и фармацевтическая композиция (варианты)
TNSN08171A1 (en) Pharmaceutical composition comprising at least one anticancer drug and at least one polymer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2327 DE 11-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.